Adagene Inc. Reports Phase 1b/2 Study Data Update
Ticker: ADAG · Form: 6-K · Filed: Jan 27, 2025 · CIK: 1818838
Sentiment: neutral
Topics: clinical-trial, data-update, foreign-issuer
TL;DR
Adagene dropped new Phase 1b/2 data, check the press release!
AI Summary
Adagene Inc. filed a Form 6-K on January 27, 2025, reporting updated data from its Phase 1b/2 study. The filing includes a press release titled "Adagene Announces Updated Data from Phase 1b/2 S", indicating new developments in their clinical trials.
Why It Matters
This filing provides investors with crucial, up-to-date information on Adagene's clinical trial progress, which can significantly impact the company's valuation and future prospects.
Risk Assessment
Risk Level: medium — Clinical trial data updates can be highly volatile, with positive results boosting stock and negative results causing significant drops.
Key Players & Entities
- Adagene Inc. (company) — Registrant
- Peter Luo (person) — Chief Executive Officer
- January 27, 2025 (date) — Filing Date
FAQ
What specific updated data was announced from the Phase 1b/2 study?
The filing references a press release titled "Adagene Announces Updated Data from Phase 1b/2 S", but the specific details of the data are not included in the provided text.
What is the primary purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer, used by Adagene Inc. to report material information to the SEC, in this case, likely related to updated clinical trial data.
Who signed this report on behalf of Adagene Inc.?
Peter Luo, Chief Executive Officer, signed the report on behalf of Adagene Inc.
What is Adagene Inc.'s principal executive office address?
Adagene Inc.'s principal executive office is located at 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu Province, 215123, People's Republic of China.
Does Adagene Inc. file annual reports under Form 20-F or Form 40-F?
Adagene Inc. indicated that it files annual reports under Form 20-F.
Filing Stats: 171 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2025-01-27 07:00:42
Filing Documents
- tm254514d1_6k.htm (6-K) — 10KB
- tm254514d1_ex99-1.htm (EX-99.1) — 14KB
- tm254514d1_ex99-1img001.jpg (GRAPHIC) — 2KB
- 0001104659-25-006124.txt ( ) — 28KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Adagene Inc. By: /s/ Peter Luo Name: Peter Luo Title: Chief Executive Officer Date: January 27, 2025 EXHIBIT INDEX Exhibit Description 99.1 Press release titled “Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA ® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium.”